Calquence (Acalabrutinib)

• Fatal and severe infections, including opportunistic infections, may occur in those with hematologic malignancies treated with Acalabrutinib. Consider prophylaxis in those who are at higher risk for opportunistic infections. Evaluate patients for signs/symptoms of infection and treat them as soon as possible. 
• Fatal and severe hemorrhagic events may occur in those with hematologic malignancies treated with calquence 100 mg. Use of antithrombotic agents concomitantly with this medication may further increase the probability of hemorrhage. Evaluate patients for signs of bleeding.
• Grade 3/4 cytopenias, including neutropenia, anemia, thrombocytopenia, and lymphopenia, may develop in those with hematologic malignancies treated with Acalabrutinib. Monitor complete blood counts (CBCs) regularly throughout the therapy. Interrupt therapy, reduce the dose, or discontinue therapy as warranted. 
• Second primary malignancies, including skin cancers and other solid tumors may occur in those exposed to Acalabrutinib. The most frequent second primary malignancy is skin cancer. Monitor patients for skin cancers and protection from sun exposure is required.
• Grade 3 atrial fibrillation or flutter may occur in those treated with Acalabrutinib, with all grades of atrial fibrillation or flutter may be reported in patients. Risk may be increased in those with hypertension, cardiac risk factors, acute infection and previous arrhythmias. Monitor for signs and symptoms of arrhythmia (e.g., dizziness, syncope, palpitations, dyspnea) and manage as required.
• Based on findings, acalabrutinib dose may cause fetal harm and dystocia is used by a pregnant woman. Female patients of reproductive age should use effective contraception during therapy with acalabrutinib and for at least 7 days after the last dose. Pregnancy testing is recommended for females of reproductive age before initiating acalabrutinib therapy.
• Females should not breastfeed during therapy with acalabrutinib and for at least 2 weeks after the last dose. Avoid the use of acalabrutinib in those with severe hepatic impairment. The safety of acalabrutinib has not been assessed in thode with moderate or severe hepatic impairment. Safety as well as efficacy in pediatric patients have not been established.

What documents are required to import CALQUENCE to India?

CALQUENCE (acalabrutinib) capsules/tablets can be imported by patients or government hospitals in the name of the patients only.

The following documentation is required to import the product:

• Valid prescription from a qualified doctor.
• Patients’ diagnostic reports.
• Patients’ ID proof (issued by the government of India).

How does order be confirmed?

The order will be confirmed only after the receipt of:

• Valid prescription of Doctor.
• Import permit if applicable.

Is CALQUENCE available in India?

CALQUENCE (acalabrutinib capsules/tablets) is a prescription drug that legally requires a medical prescription to be dispensed.

Urgent Meds facilitates the import of cancer medicines on the named patient supply. Urgent Meds provides input on:

• Availability of Calquence in India (Mumbai, Pune, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, and Bangalore etc.)
• Medicine Price.
• Finding Genuine and reliable sources from Canada, Europe, USA, and Australia.
• Ensuring 100% transparency.

CALQUENCE can be made available to patients, doctors, and hospitals in Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Srinagar, Jammu, Jaipur, Chandigarh, Ludhiana, Noida, Gurgaon, Lucknow, Pune, and other cities in India. The order will be confirmed only after the receipt of a valid prescription from the doctor and import permit.

Urgent Meds can facilitate the supply of CALQUENCE (prescription medicines) to all locations in the world and in India after fulfilling the legal requirement (if applicable).

Please contact +1-647-818-4196 or write us at info@urgentmeds.in for Calquence 100 mg price in India.

We take guarantee of quality and delivery anywhere in the world as per the buyer’s requirements.

Ugrent Meds is able to source the CALQUENCE (Cancer Treatment Medicines) from across the globe, and has the ability to supply. Indian Pharma Network offers its customers worldwide access to the best available treatment.

Urgent Meds is able to dispense any valid prescription in the shortest possible time. All prescriptions are dispensed and checked by registered pharmacists and dispatched to the Patient’s address only from New Delhi, India.

What is the Generic Name for the trade name drug Calquence®?

Acalabrutinib is the Generic Name for the trade name drug Calquence®.

What is the Manufacturer Name of Calquence®?

Calquence® is manufactured by AstraZeneca Pharmaceuticals LP.

Is Calquence® approved by the FDA?

Yes, Calquence® is approved by the FDA. Date of approval: January 2017.

What is the dosage and form of Calquence® supplied?

Calquence® is supplied as Capsules: 100 mg for oral administration.

Where can I get Calquence® at the best price in India?

To get the best Calquence price in India, please contact Urgent Meds (a WHO-GDP and ISO certified Company). A medical prescription is required while buying Calquence®.

What are the most common side effects with Calquence®?

The most common side effects with Calquence® are: headache, anemia, neutropenia, upper respiratory tract infection, thrombocytopenia, musculoskeletal pain, and diarrhea.

How much does Calquence® cost in India?

Calquence® (acalabrutinib) cost in India is less and can vary. In order to buy/procure this medication authentically, you can Call/WhatsApp +1-647-818-4196 or send mail to info@urgentmeds.in.

What are the storage conditions of Calquence®?

Store Calquence capsules/tablets at 20-25°C (68-77°F); excursions permitted to 15-30°C (59-86°F).

Is it safe to buy Calquence® online from India?

Yes, you can buy Calquence online in India at the best price from Urgent Meds if Calquence® has not been approved or is not available in your country.